Intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas: analysis of the clinicopathologic features and prognosis

doi:10.16150/j.1671-2870.2018.03.009

Abstract

Abstract: Objective: To evaluate the clinicopathologic features and prognosis of intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas. Methods: The clinical data, pathological features and prognosis of 52 patients were studied retrospectively. Results: Of all the 52 cases, 36 lesions were located in the head of pancreas, 15 were in the body/tail, and 1 was in the entire length of the pancreatic duct. The median age of these patients was 65 years. Of the 52 IPMNs, 23 cases were the gastric type, 12 cases were intestinal, 9 cases were pancreatobiliary, 7 cases were mixed type (gastric+pancreatobiliary type) and 1 case was oncocytic. The types of invasive carcinoma included 37 cases of ductal adenocarcinomas, 13 cases of colloid carcinomas, 1 cases of undifferentiated carcinoma and 1 cases of adenosquamous carcinoma. Elevated serum CA19-9 level was more frequent in patients with ductal adenocarcinoma. Nine of 52 patients were lost to follow-up. The median postoperative follow-up period was 16 months (range 5-57 months). Conclusions: The intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas are mainly ductal adenocarcinoma. Elevated serum CA19-9 level is associated with the types of the invasive carcinoma. The positive lymph nodes and tumor extending beyond pancreas are risk factors for the poor prognosis.

Key words: Intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas, Clinical, Pathology, Prognosis

CLC Number:

R735.9

WANG Ting, XIE Wen, LIN Xiaozhu, YUAN Fei, WANG Chaofu, GUO Yan. Intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas: analysis of the clinicopathologic features and prognosis[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 278-284.

References

[1] Bosman FT, Carneiro F, Hruban RH, et al.WHO Classification of Tumours of the Digestive System[M]. Lyon: IARC Press,2010.
[2] Noë M, Brosens LA.Pathology of Pancreatic Cancer Precursor Lesions[J]. Surg Pathol Clin,2016,9(4):561-580.
[3] Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas[J]. Pancreatology,2012,12(3):183-197.
[4] Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas[J]. Pancrea-tology,2017,17(5):738-753.
[5] Nakagohri T, Asano T, Kenmochi T, et al.Long-term surgical outcome of noninvasive and minimally invasive intraductal papillary mucinous adenocarcinoma of the pancreas[J]. World J Surg,2002,26(9):1166-1169.
[6] Kitagawa Y, Unger TA, Taylor S, et al.Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas[J]. J Gastrointest Surg,2003,7(1):12-19.
[7] Katabi N, Klimstra DS.Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach[J]. J Clin Pathol,2008,61(12):1303-1313.
[8] Yamada S, Fujii T, Shimoyama Y, et al.Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm[J]. Ann Surg Oncol,2014,21(7):2444-2452.
[9] Morales-Oyarvide V, Mino-Kenudson M, Ferrone CR, et al.Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes[J]. J Gastrointest Surg,2018,22(2):226-234.
[10] Furukawa T, Hatori T, Fujita I, et al.Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas[J]. Gut,2011,60(4):509-516.
[11] Feng F, Tian Y, Xu G, et al.Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer[J]. BMC Cancer,2017,17(1):737.
[12] Takahara N, Nakai Y, Isayama H, et al.CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer[J]. Cancer Chemother Pharmacol,2017,80(6):1105-1112.
[13] Veisi Malekshahi Z, Amani J, Negahdari B, et al.Design, expression and evaluation of novel chimeric protein constructed from colorectal tumor-associated antigen[J]. J Cell Biochem,2018,119(4):3464-3473.
[14] New Biomarker Identified for PDAC[J]. Cancer Discov,2017,7(9):OF3.
[15] Kim JR, Jang JY, Kang MJ, et al.Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas[J]. J Hepatobi-liary Pancreat Sci,2015,22(9):699-707.
[16] You L, Ma L, Zhao WJ, et al.Emerging role of tumor markers and biochemistry in the preoperative invasive assessment of intraductal papillary mucinous neoplasm of the pancreas[J]. Clin Chim Acta,2016,454:89-93.
[17] Hirono S, Kawai M, Okada K, et al.Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas[J]. Surgery,2016,160(2):306-317.
[18] Distler M, Kersting S, Niedergethmann M, et al.Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas[J]. Ann Surg,2013,258(2):324-330.
[19] Roch AM, Ceppa EP, Al-Haddad MA, et al.The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression[J]. Ann Surg,2014,260(4):680-690.
[20] Larghi A, Panic N, Capurso G, et al.Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas[J]. Ann Oncol,2013,24(7):1907-1911.
[21] Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes[J]. Gut,2011,60(12):1712-1720.
[22] Duconseil P, Périnel J, Autret A, et al.Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC)[J]. Eur J Surg Oncol,2017,43(9):1704-1710.
[23] Bhardwaj N, Dennison AR, Maddern GJ, et al.Management implications of resection margin histology in patients undergoing resection for IPMN: A meta-analysis[J]. Pancreatology,2016,16(3):309-317.
[24] Yamaguchi J, Kaneoka Y, Maeda A, et al.Positive surgical margins in surgically treated unifocal and multifocal IPMN[J]. Int J Surg,2016,28:51-55.
[25] Yamanaka K, Masuda A, Toyama H, et al.Association between serum SPan-1 and lymph node metastasis in invasive intraductal papillary mucinous neoplasm of the pancreas[J]. Pancreatology,2017,17(1):123-129.
[26] Rezaee N, Barbon C, Zaki A, et al.Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancrea-tic ductal adenocarcinoma[J]. HPB(Oxford),2016,18(3):236-246.
[27] Saito M, Hirokawa N, Usami Y, et al.Differential diagnosis between intraductal papillary mucinous neoplasm with an associated invasive carcinoma and pancreatic ductal adenocarcinoma on ultrasonography: the utility of echo intensity and contrast enhancement[J]. Ultrasonography,2017,36(3):260-269.